EGFR and non-small cell lung carcinoma: Indeed, 27–31% of patients with non-small-cell lung cancer (NSCLC) may be unable to provide a biopsy sample suitable for epidermal growth factor receptor (EGFR) mutation analysis at diagnosis [2] or following disease progression.